Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 25 of 30
Sensitivity to Intravenous Nicotine: Genetic Moderators
NCT00969137
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)
NCT01070160
Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
NCT00935493
Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates
NCT01050660
Hormones and Physical Exercise (HOPE) Study
NCT02056067
Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET
NCT01719497
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
NCT00920309
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
NCT00821951
Registry of Pregnancies Conceived Following Exposure to Ovulation Stimulation Medications
NCT00902382
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
NCT00814879
Women's Activity and Lifestyle Study in Connecticut
NCT02107066
Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma
NCT00698776
Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk
NCT00861146
Changing Lifestyles for Better Health
NCT00848757
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
NCT00858962
Effects of Salvinorin A in Healthy Controls
NCT00700596
Effects of Delta-9-THC and Iomazenil in Healthy Humans
NCT00982982
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
NCT00588731
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
NCT00844883
Investigation of Naltrexone for Pathological Gambling
NCT01057862
Ketamine Infusion for Obsessive-Compulsive Disorder
NCT01349231
Mindfulness Training for Smoking Cessation
NCT01144689
Pregnancy in Polycystic Ovary Syndrome II
NCT00719186
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
NCT00730483
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
NCT00744055
Chronic Alcohol and Brain Stress Circuit Response
NCT01031264
Stress Reactivity in Veterans Receiving Pharmacological Treatment for PTSD and Alcohol Dependence
NCT00923923
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
NCT00785798
Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation
NCT01799330
Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia
NCT00793780
The Impact of Pancreatic Islet Cell Allotransplantation on Cognitive Function in Type 1 Diabetes Mellitus
NCT00590876
A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)
NCT00809523
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
NCT00703807
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
NCT00719875
Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care
NCT00829283
The Impact of Active Nurse Participation on Adenoma Detection During Routine Colonoscopy
NCT00859625
Modeling Stress-precipitated Smoking Behavior for Medication Development
NCT00773357
Biological Clock Dysfunction in Optic Nerve Hypoplasia
NCT00825591
Domperidone in Refractory Gastroparesis
NCT00760461
Dronabinol Interactions With Cognitive Enhancing Drug in Humans
NCT00842985
Transitions: Linkages From Jail To Community
NCT00841711
Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
NCT00913770
Implementation of Practice Standards for ECG Monitoring
NCT01269736
Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)
NCT00743574
Transvaginal Appendectomy
NCT00806429
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
NCT01600885
Chronic Pain and Opioid Dependence Assessment and Treatment
NCT00727675
Impact of Oral Contraceptives on GABA and Neurosteroids
NCT00656318
Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
NCT00555425
Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women
NCT00628771
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.